Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although many patients with venous thromboembolism require extended treatment, it is uncertain whether it is better to use full- or lower-intensity anticoagulation therapy or aspirin. METHODS: In this randomized, double-blind, phase 3 study, we assigned 3396 patients with venous thromboembolism to receive either once-daily rivaroxaban (at doses of 20 mg or 10 mg) or 100 mg of aspirin. All the study patients had completed 6 to 12 months of anticoagulation therapy and were in equipoise regarding the need for continued anticoagulation. Study drugs were administered for up to 12 months. The primary efficacy outcome was symptomatic recurrent fatal or nonfatal venous thromboembolism, and the principal safety outcome was major bleeding. RESULTS: A total of 3365 patients were included in the intention-to-treat analyses (median treatment duration, 351 days). The primary efficacy outcome occurred in 17 of 1107 patients (1.5%) receiving 20 mg of rivaroxaban and in 13 of 1127 patients (1.2%) receiving 10 mg of rivaroxaban, as compared with 50 of 1131 patients (4.4%) receiving aspirin (hazard ratio for 20 mg of rivaroxaban vs. aspirin, 0.34; 95% confidence interval [CI], 0.20 to 0.59; hazard ratio for 10 mg of rivaroxaban vs. aspirin, 0.26; 95% CI, 0.14 to 0.47; P<0.001 for both comparisons). Rates of major bleeding were 0.5% in the group receiving 20 mg of rivaroxaban, 0.4% in the group receiving 10 mg of rivaroxaban, and 0.3% in the aspirin group; the rates of clinically relevant nonmajor bleeding were 2.7%, 2.0%, and 1.8%, respectively. The incidence of adverse events was similar in all three groups. CONCLUSIONS: Among patients with venous thromboembolism in equipoise for continued anticoagulation, the risk of a recurrent event was significantly lower with rivaroxaban at either a treatment dose (20 mg) or a prophylactic dose (10 mg) than with aspirin, without a significant increase in bleeding rates. (Funded by Bayer Pharmaceuticals; EINSTEIN CHOICE ClinicalTrials.gov number, NCT02064439 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Consequently, several studies have investigated the role of aspirin for the secondary prevention of VTE. 309,314,315”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“Two of these agents, rivaroxaban and apixaban, have been studied at a reduced dose: from 20 mg daily to 10 mg daily for rivaroxaban and 5 mg to 2.5 mg twice daily for apixaban. 306,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“We identified 2 RCTs 306,314 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“and a single study comparing 2 doses of the direct oral anticoagulant rivaroxaban and aspirin found that anticoagulation was more effective than aspirin without an increase in bleeding rates. 314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Self-citationSCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Self-citationSCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Self-citationThe Statistical Analysis of Failure Time Data
Klein, J. P. (1982) · Technometrics · doi:10.1080/00401706.1982.10487769 · Cited by 2,215
Research works printed but not linked: 1
- 2012, MMWR Morb Mortal Wkly Rep, 61, 401
Cited by
Items 401–500 of 786
Scott, L. C., Li, J., Cafuir, L. A., Gaddh, M., & Kempton, C. L. (2022) · eJHaem · doi:10.1002/jha2.418 · Cited by 5
Gao, J., Hu, F., Cheung, S. H., & Su, P. (2022) · Statistical Methods in Medical Research · doi:10.1177/09622802221095244 · Cited by 5
Non-vitamin K antagonist oral anticoagulants for pulmonary embolism: who, where and for how long?
Howard, L. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2018.1452614 · Cited by 5
Rodríguez, P. D., Valle, F. G., García-Fernández-Bravo, I., Ruiz, S. P., Alvarez-Sala-Walther, L. A., & del Toro‐Cervera, J. (2019) · Medicine · doi:10.1097/md.0000000000014093 · Cited by 8
Lobastov, K. V. (2019) · Pirogov Russian Journal of Surgery · doi:10.17116/hirurgia201905194 · Cited by 5
Outpatient Treatment for Deep Vein Thrombosis with Rivaroxaban: A Single-Center Experience
Lobastov, K. V., Vorontsova, A. V., Bargandzhiya, A., Schastlivtsev, I., & Laberko, L. A. (2020) · Journal of Venous Disorders · doi:10.17116/flebo20201402199 · Cited by 5
Gallo, A., Valerio, L., & Barco, S. (2021) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytaa542 · Cited by 5
Management of Patients With Venous Thromboembolism After the Initial Treatment Period
Fernandes, T. M., Kanwar, M. K., & White, R. (2021) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2021.02.200085 · Cited by 6
Shaydakov, M. E., Ting, W., Sadek, M., Aziz, F., Diaz, J. A., Comerota, A. J., Lurie, F., Blebea, J., Eklöf, B., Lugli, M., et al. (2022) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2022.03.013 · Cited by 6
Unprovoked Venous Thromboembolism
Mwansa, H., Zghouzi, M., & Barnes, G. D. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2023.05.006 · Cited by 6
Gary, T. (2019) · Learning materials in biosciences · doi:10.1007/978-3-030-12270-6_11 · Cited by 5
Palareti, G., Antonucci, E., Ageno, W., Mastroiacovo, D., Poli, D., & Tosetto, A. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14300 · Cited by 5
Major acute cardiovascular events after venous thromboembolism: a meta-analysis of randomized trials
Becattini, C., & Vedovati, M. C. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.02.023 · Cited by 4
Venöse Thromboembolie – was ist neu in der aktualisierten AWMF-Leitlinie?
Linnemann, B., Mühlberg, K. S., & Klamroth, R. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2128-0005 · Cited by 4
Vichaidit, K., Chantrathammachart, P., Niparuck, P., Puavilai, T., Angchaisuksiri, P., & Boonyawat, K. (2024) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2024.102643 · Cited by 4
Hosokawa, K., & Abe, K. (2025) · Journal of Cardiology · doi:10.1016/j.jjcc.2025.03.006 · Cited by 7
Xiong, W. G., Yamashita, Y., Horie, T., & Ono, K. (2025) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-025-03103-4 · Cited by 4
Bilal, A. R., Umar, S. A., Arfin, S. M. W., Bilal, A. R., Sajid, M., Gaba, H., Qureshi, S., Inam, M. H., & Waqas, S. A. (2025) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-025-03172-5 · Cited by 4
Mahmoud, A. A., Eltaher, B., Shah, P., Vengilote, R., Mostafa, M. A. O., Afzal, A., & Sanfilippo, K. M. (2025) · American Journal of Hematology · doi:10.1002/ajh.70090 · Cited by 4
Nicoletto, M., Maino, A., Guarascio, M., Cavalleri, M., Gallucci, F., Dentali, F., & Pomero, F. (2026) · Thrombosis Research · doi:10.1016/j.thromres.2026.109669 · Cited by 4
Stopping anticoagulation in a woman with unprovoked venous thromboembolism
Khan, F. A., Gal, G. L., & Rodger, M. A. (2017) · Canadian Medical Association Journal · doi:10.1503/cmaj.170327 · Cited by 4
Results of treatment with oral anticoagulants in patients with lower limb deep vein thrombosis
Полянцев, А. А., Frolov, D. V., Линченко, Д. В., Shchelokova, I. V., Litvinova, T. A., & Дьячкова, Ю. А. (2020) · Angiology and vascular surgery · doi:10.33529/angi02020208 · Cited by 4
Bozkurt, A. K., Akay, H. T., Çalkavur, T., Şırlak, M., Balkanay, O. O., Uğuz, E., Doğancı, S., Polat, A., Bayrak, S., Bozok, Ş., et al. (2021) · Turkish Journal of Thoracic and Cardiovascular Surgery · doi:10.5606/tgkdc.dergisi.2021.22121 · Cited by 6
Groat, D., Martin, K. A., Rosovsky, R. P. G., Sanfilippo, K. M., Gaddh, M., Kreuziger, L. B., Eyster, M. E., & Woller, S. C. (2022) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12740 · Cited by 4
Liu, M., Qiu, X., Sun, Y., Li, Q., Wen, J., Liu, G., Yao, Z., & Zhu, L. Y. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.09.014 · Cited by 4
Anticoagulant therapy in renal insufficiency theme: Anticoagulation in complex situations
Parks, A. L., Stevens, S. M., & Woller, S. C. (2024) · Thrombosis Research · doi:10.1016/j.thromres.2024.109097 · Cited by 4
Laganà, A., Sorella, S., Fucci, L., Santoro, C., Ligia, S., Mormile, R., Baldacci, E., & Chistolini, A. (2024) · Annals of Hematology · doi:10.1007/s00277-024-06021-2 · Cited by 4
del Pozo, M. M., Asenjo, M. M., Franco‐Moreno, A., de Antonio, E. U., & Valle, F. G. (2024) · Revista Clínica Española · doi:10.1016/j.rce.2024.07.007 · Cited by 4
Boccatonda, A., Simion, C., Brighenti, A., Serra, C., Simioni, P., & Campello, E. (2025) · Thrombosis Research · doi:10.1016/j.thromres.2025.109403 · Cited by 4
The history and historical treatments of deep vein thrombosis: toward the era of new anticoagulants
Galanaud, J. ‐., Laroche, J.-P., & Righini, M. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.07.019 · Cited by 5
Ahmed, M., Zulfiqar, E., Ashraf, H., Hashmi, T. M., Ahmed, R., Rana, J. S., Greene, S. J., Mentz, R. J., Fudim, M., & Fonarow, G. C. (2025) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2025.102996 · Cited by 4
Billur, R., Ban, D., Sabo, T. M., & Maurer, M. C. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00970 · Cited by 4
The year in cardiology 2017: prevention
Nordestgaard, B. G., Cosentino, F., Landmesser, U., & Laufs, U. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx766 · Cited by 4
Initial and Long-Term Treatment of Pulmonary Embolism: Current Approach and Future Perspectives
Ageno, W., & Donadini, M. P. (2018) · Hämostaseologie · doi:10.1055/s-0038-1641605 · Cited by 4
Kanaan, D. M., Cook, B. M., Kelly, J., & Malloy, R. J. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.04.009 · Cited by 4
Practical guidance for new multiple myeloma treatment regimens: A nursing perspective
Epstein, M., & Morrison, C. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.010 · Cited by 5
Abdulrehman, J., Forté, S., TOMLINSON, G. A., Solh, Z., Bolster, L., Sun, H., Bartolucci, P., & Kuo, K. H. M. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-079363 · Cited by 5
Analysis of Sex Hormones, Insulin Dosage, and Risk Factors Associated With Male Diabetic Patients
Chen, X.-J. (2024) · American Journal of Men s Health · doi:10.1177/15579883241235062 · Cited by 5
Robin, P., Eddy, M., Sikora, L., Roux, P. L., Carrier, M., Couturaud, F., Planquette, B., Pesavento, R., Rodger, M. A., Salaün, P., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-023939 · Cited by 5
Jennings, S.-L. T., Manh, K. N. P., & Bita, J. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019851358 · Cited by 4
Beneki, E., Vrysis, C., Zintzaras, E., & Doxani, C. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02315-0 · Cited by 9
Advances in the Management of Acute Venous Thromboembolism and New Therapeutic Agents
Stevens, H., McFadyen, J. D., & Chan, N. (2021) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1723953 · Cited by 5
A case of acute pulmonary embolism with severe haemoptysis
Mao, R. L., Tromeur, C., & Couturaud, F. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.05.011 · Cited by 6
Characteristics of patients receiving extended treatment after incident venous thromboembolism
Albertsen, I. E., Jensen, M., Abdelgawwad, K., Søgaard, M., Larsen, T. B., & Nielsen, P. B. (2021) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13637 · Cited by 4
Zakai, N. A., Walker, R. F., MacLehose, R. F., Koh, I., Alonso, Á., & Lutsey, P. L. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12575 · Cited by 4
Beinvenenthrombose und Lungenembolie: Diagnostik und Therapie
Bauersachs, R. M. (2022) · Der Internist · doi:10.1007/s00108-022-01349-1 · Cited by 6
Self-citationJacobson, J. D., & Weinberg, I. (2020) · Springer eBooks · doi:10.1007/978-3-030-45792-1_11 · Cited by 4
Hobohm, L., & Lankeit, M. (2021) · Pneumologie · doi:10.1055/a-1029-9937 · Cited by 4
Reduced-Intensity Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism
Crowther, M. A., & Cuker, A. C. (2017) · New England Journal of Medicine · doi:10.1056/nejme1701628 · Cited by 4
Campello, E., Cappugi, C., Catalani, F., Poli, D., & Bucciarelli, P. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2632-3197 · Cited by 6
Deleenheer, B., Cuerda, C., Jeppesen, P. B., Joly, F., Lal, S., Lamprecht, G., Mundi, M. S., Szczepanek, K., Vanassche, T., der Linden, L. R. V., et al. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.07.1126 · Cited by 3
Nonanticoagulant Strategies for Venous Thromboembolism Prophylaxis
Gurumurthy, G., & Thachil, J. V. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2712-3534 · Cited by 5
Tratamiento de la trombosis venosa profunda de extremidades inferiores
Trujillo‐Santos, J. (2020) · Revista Clínica Española · doi:10.1016/j.rce.2020.05.009 · Cited by 10
Chazova, I. E., Martynyuk, T. V., Горбачевский, С. В., Владимирович, Г. В., Danilov, N. M., Панченко, Е. П., Chernyavskiy, A. М., Shmalts, A. A., & Yavelov, I. S. (2022) · Terapevticheskii arkhiv · doi:10.26442/00403660.2022.09.201836 · Cited by 3
Palareti, G., Antonucci, E., Bucherini, E., Caronna, A., Chistolini, A., Giorgio, A. D., Giulio, R. D., Falanga, A., Fregoni, V., Garzia, M., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051343 · Cited by 3
Gołąb, A., Plicner, D., Konieczyńska, M., Broniatowska, E., & Undas, A. (2024) · Medicine · doi:10.1097/md.0000000000038697 · Cited by 3
Oral Anticoagulants in Women: What's the Difference? A Narrative Review
Faioni, E. M., & Scimeca, B. (2025) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296251347938 · Cited by 3
NOACs for VTE prevention in patients with lower limb fracture: a systematic review and meta-analysis
Wu, B., Sun, L., Wu, W., Cao, J., Chen, Y., & Yan, C. (2025) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-025-06092-5 · Cited by 3
Länger, F. P., Hart, C., Klima, K., Marten, S., Mühlberg, K. S., Pfrepper, C., & Bauersachs, R. M. (2025) · Hämostaseologie · doi:10.1055/a-2645-4927 · Cited by 3
Self-citationCavallaro, C., Santini, P., Leoni, L., Mosoni, C., D’Ambrosio, S., Mancinetti, F., Coletta, N., Iorio, M., Porfidia, A., D’Errico, A., et al. (2025) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-025-03182-3 · Cited by 3
Strategien zur Antikoagulation bei Patienten mit tiefer Beinvenenthrombose und Lungenarterienembolie
Radke, P. W., & Möckel, M. (2017) · Herz · doi:10.1007/s00059-017-4655-1 · Cited by 3
VTE and anticoagulation in menstruating women
Micaily, I., & Bannow, B. S. (2021) · Thrombosis Update · doi:10.1016/j.tru.2021.100088 · Cited by 3
Miyagawa, M., Okumura, Y., Fukamachi, D., Fukuda, I., Nakamura, M., Yamada, N., Takayama, M., Maeda, H., Yamashita, T., Ikeda, T., et al. (2022) · International Heart Journal · doi:10.1536/ihj.21-390 · Cited by 3
Are outpatient anticoagulation management services the wave of the future (again)?
Bannow, B. S. (2022) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12735 · Cited by 3
Management of Thromboembolic Disease in Patients with Primary and Metastatic Brain Tumors
Woods, R. R., & Lesser, G. J. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01116-w · Cited by 3
Hemostatic considerations for gender affirming care
Garland, K., Mullins, E. S., Bercovitz, R. S., Rodriguez, V., Connors, J. M., & Sokkary, N. A. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.09.002 · Cited by 7
Ren, J., Wang, N., Zhang, X., Song, F., Zheng, X. M., & Han, X. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05767-z · Cited by 3
Laganà, A., Fucci, L., Sorella, S., Santoro, C., & Chistolini, A. (2024) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000001321 · Cited by 3
Brenner, B., Tzoran, I., Bikdeli, B., Valle, R., Poénou, G., Tirado-Miranda, R., Pesce, M. L., Escribano, J. P., Giorgi‐Pierfranceschi, M., Monréal, M., et al. (2024) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0044-1791817 · Cited by 4
Osti, N., Racanelli, V., Susca, N., Martinelli, N., & Maino, A. (2024) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2024.101565 · Cited by 3
Dobesh, P. P., Volkl, A. A., Pap, A. F., Damaraju, C. V., Levitan, B. S., Yuan, Ž., & Amin, A. N. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01192-7 · Cited by 4
Self-citationReport of the Annual Scientific Sessions of the American College of Cardiology (ACC), Washington DC
Hiro, T. (2017) · Circulation Journal · doi:10.1253/circj.cj-17-0416 · Cited by 3
Giustozzi, M., Vedovati, M. C., & Agnelli, G. (2018) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000697 · Cited by 3
Fayol, A., Lanéelle, D., Hoffmann, C., Mahé, G., & Mahé, I. (2019) · VASA · doi:10.1024/0301-1526/a000789 · Cited by 3
Бурлева, Е. П., & Kremenevskiy, O. M. (2019) · Journal of Venous Disorders · doi:10.17116/flebo20191301142 · Cited by 3
Ahnström, J., Gierula, M., Temenu, J., Laffan, M., & Lane, D. A. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14627 · Cited by 3
Extended oral anticoagulation after incident venous thromboembolism – a paradigm shift?
Albertsen, I. E., Piazza, G., Søgaard, M., Nielsen, P. B., & Larsen, T. B. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1755260 · Cited by 3
Krumb, E., & Hermans, C. R. J. R. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12479 · Cited by 3
Place actuelle des anticoagulants oraux directs dans la maladie thromboembolique veineuse
Roffé, A., Guédon, A. F., & Lallmahomed, E. (2021) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2021.06.005 · Cited by 4
Lasica, R., Ašanin, M., Djukanovic, L., Radovanović, N., Savić, L., Polovina, M. M., Stankovic, S. D., Ristić, A. D., Zdravkovic, M. D., Lasica, A., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15091146 · Cited by 6
Krumme, A. A., Pawar, A. M., Schneeweiß, S., Glynn, R. J., Choudhry, N. K., Kulldorff, M., Ortiz, A. S., Avorn, J., & Gagne, J. J. (2017) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2017-0053 · Cited by 3
Extended Treatment of Venous Thromboembolism
Weitz, J. I., Lensing, A. W. A., & Prins, M. H. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1705484 · Cited by 3
Self-citationBien, J. Y., Tao, D. L., Daughety, M. M., DeLoughery, T. G., & Shatzel, J. J. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1648-8 · Cited by 3
Anticoagulation Beyond 3 to 6 Months: What Does the Data Tell Us?
Carman, T. L. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.04.002 · Cited by 3
Advances in Clinical Cardiology 2017: A Summary of Key Clinical Trials
McQuillan, C., Gray, A. P., Kearney, A., & Menown, I. B. A. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0716-y · Cited by 3
Outpatient Oral Anticoagulant Therapy
Ansell, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00037-6 · Cited by 4
Pulmonary artery thrombosis: strategy of anticoagulation
Porembskaya, О. Y., Кравчук, В. Н., Lobastov, K. V., Kuzmina-Krutetskaya, S. R., Laberko, L. A., Chesnokov, M. S., Velikanova, K. E., & Saiganov, S. A. (2021) · Pirogov Russian Journal of Surgery · doi:10.17116/hirurgia202111176 · Cited by 4
The secondary prevention of venous thromboembolism: Towards an individual therapeutic strategy
Elmi, G., Pizzini, A. M., & Silingardi, M. (2018) · Vascular · doi:10.1177/1708538118776896 · Cited by 3
Introduction to the Vascular Medicine Issue of Progress in Cardiovascular Diseases
Kim, E., & Beckman, J. A. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.04.003 · Cited by 4
Herold, J., & Bauersachs, R. M. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15426 · Cited by 3
Self-citationSerrao, A., Assanto, G. M., Malfona, F., Orellana, G. C., & Chistolini, A. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15775 · Cited by 3
Kumbhani, D. J., Armbruster, A. L., Cheng, R. K., Chrispin, J., Fischer, U., Holbrook, A. M., Joglar, J., & Sevestre, M.-A. (2026) · JACC · doi:10.1016/j.jacc.2026.05.033 · Cited by 2
Wang, C., Fan, X., Nie, L., Wang, Q., Li, S., Zheng, W., Zhang, W., Dai, W., & Chen, M. (2024) · Clinical Interventions in Aging · doi:10.2147/cia.s405075 · Cited by 2
Roux, P. L., Robin, P., Pennec, R. L., Tromeur, C., Couturaud, F., Asselineau, J., Gal, G. L., & Salaün, P. (2025) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2025.102867 · Cited by 2
New horizons in the pharmacological management of venous thromboembolism
Verstraete, A., Thillo, Q. V., Vanassche, T., & Verhamme, P. B. (2025) · HemaSphere · doi:10.1002/hem3.70143 · Cited by 2
Self-citationSuperdock, M., Moll, S., & Wilson, S. (2025) · The Hematologist · doi:10.1182/hem.v22.4.2025411 · Cited by 2
Practical guide to management after an acute pulmonary embolism
Alikhan, R., Howard, L., Johnson, M., Sweeney, S., Kiely, D. G., & Pepke‐Żaba, J. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-003028 · Cited by 2
Delluc, A., Carrier, M., Lauw, M. N., Cuker, A. C., Bertoletti, L., Beyer‐Westendorf, J., Nisio, M. D., Simard, C., Roberge, G., Harrigan, A. M., et al. (2025) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000001388 · Cited by 2
Self-citationArifi, M. A., Alshahrani, W. A., Alshehri, A. M., & Yami, M. S. A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020770 · Cited by 2
Taree, N. A., Lee, A., Sivak, A., Rich, R., Zhu, N. Y., Sun, H., & Wu, C. M. (2026) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2026.01.030 · Cited by 2
Metadata
- Authors
- Weitz, J. I., Lensing, A. W. A., Prins, M. H., Bauersachs, R., Beyer-Westendorf, J., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., Freitas, M. C. S., Holberg, G., Kakkar, A. K., Haskell, L., van Bellen, B., Pap, A. F., Berkowitz, S. D., Verhamme, P., Wells, P. S., & Prandoni, P.
- Affiliations
- University of Ottawa (CA)
- University of Geneva (CH)
- University of Padua (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-03-30
- Volume
- 376
- Issue
- 13
- Pages
- 1211-1222
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2595086780
- Cited by
- 787
- References
- 32
- Citations by year
- 2026: 58 · 2025: 77 · 2024: 65 · 2023: 49 · 2022: 78 · 2021: 97 · 2020: 92 · 2019: 96 · 2018: 123 · 2017: 50
- FWCI
- 104.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- IRIS (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Ionis Pharmaceuticals
- Janssen Scientific Affairs
- Novo Nordisk
- Novo Nordisk Fonden (NNF12OC1015957)
- LEO Pharma
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- venous thromboembolism, rivaroxaban, aspirin, long-term anticoagulation, recurrent venous thromboembolism, major bleeding, low-dose rivaroxaban, thromboprophylaxis, direct oral anticoagulants, adverse events, dose comparison, post-thrombotic syndrome
- MeSH terms
- Rivaroxaban, Adult, Aged, Aspirin, Double-Blind Method, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Kaplan-Meier Estimate, Venous Thromboembolism, Secondary Prevention, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.